Plus TherapeuticsFRA:XMP1 +3.72%22 Shareholder Yield % is -134.43% as of Mar. 2026. GuruFocus rates FRA:XMP1 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,303 Biotechnology companies, Plus Therapeutics ranks worse than 95.4% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Plus Therapeutics's Shareholder Yield % was -134.43%.
Plus Therapeutics (FRA:XMP1) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Plus Therapeutics Shareholder Yield % Related Terms
Plus Therapeutics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Plus Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:XMP1 vs GRCE, NNVC, ATNM: Shareholder Yield % Comparison
For the Biotechnology subindustry, Plus Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Plus Therapeutics (FRA:XMP1) has a Shareholder Yield % of -134.43% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Plus Therapeutics and its competitors. According to the industry distribution chart, Plus Therapeutics ranks #1243 out of 1303 companies in the Biotechnology industry, placing it in the top 95.4%.
Is Plus Therapeutics' Shareholder Yield % too high?
Plus Therapeutics' current Shareholder Yield % is -134.43%. Based on the distribution chart, Plus Therapeutics ranks #1243 out of 1303 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Plus Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Shareholder Yield % compare to GRCE and NNVC?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #1243 out of 1303 companies for Shareholder Yield %. This places Plus Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Plus Therapeutics and its competitors. Plus Therapeutics's current Shareholder Yield % is -134.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (FRA:XMP1) has a current Shareholder Yield % of -134.43%. The current Shareholder Yield % is -134.43%. Plus Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Plus Therapeutics (FRA:XMP1), the current Shareholder Yield % is -134.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
22GF Score
Get the complete analysis for FRA:XMP1
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XMP1 has been successfully added to your 
